Opinion | In China’s pragmatic energy security vision, fossil fuels remain vital



Energy security is once again at the very heart of the global geopolitical arena. In an era defined by conflict, sanctions and increasingly precarious maritime routes, Beijing has internalised a fundamental truth: in an unstable world, resilience trumps ideology.

While much of the West remains locked in a debate over the pace of the energy transition, China is quietly forging a multilayered “energy shield”, designed not to choose between old and new systems, but to immunise its economy against external shocks and price turbulence.
The 2025 production figures tell a story of strategic intent. China’s oil and gas output reached record highs last year, driven by rapid growth in offshore extraction and unconventional shale resources. This reflects sustained policy support aimed at strengthening domestic supply capacity.

Every barrel pumped at home is one that does not have to navigate a contested strait or fall prey to the volatility of global markets. While domestic supply cannot yet achieve total self-sufficiency, it provides a critical strategic buffer, ensuring geopolitical friction abroad does not easily translate into industrial disruption at home.

At the same time, China has not retreated from global energy markets. Instead, it is managing its exposure more actively. The allocation of crude import quotas to refiners shows how Beijing continues to shape the flow of oil into the country. These quotas are more than administrative details; they are instruments through which the government can influence stock building, refinery utilisation and the balance between domestic and imported supply.
  • Related Posts

    Stablecoins, wealth platforms launched at Consensus 2026 amid tighter Beijing oversight

    As Consensus 2026 officially kicks off in Hong Kong this week, digital asset firms are rolling out product updates to coincide with one of the industry’s most significant events. Digital…

    Continue reading
    Capital injection: China backs AI drug makers in self-reliance drive

    Hangzhou-based METiS TechBio, founded in 2020, raised 400 million yuan (US$57.9 million) in series D financing in August last year, led by the Beijing Medical and Health Industry Investment Fund…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *